Cerapedics completed a $22 million financing round to accelerate commercialization of its i-FACTOR Peptide Enhanced Bone Graft for degenerative disc disease.
Here are three insights:
1. KCK Group led the financing round, which will also help support the investigational device exemption clinical trial of i-FACTOR in transforaminal lumbar interbody fusion surgery.
2. Cerapedics previously received FDA premarket approval for the use of i-FACTOR Peptide in anterior cervical discectomy and fusion procedures, becoming the first PMA-approved bone graft with this indication.
3. Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary biomimetic small peptide (P-15) technology platform. i‑FACTOR is the only biologic bone graft to incorporate a small peptide as an attachment factor to stimulate the natural bone healing process.
Here is more information on the i-FACTOR Peptide Enhanced Bone Graft.
More articles on biologics:
17 major players in the global spine biologics market
Dr. Chad Lavender performs ACL repair with bone marrow: 3 things to know